26 January 2025 : Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Antibody Titers
Yoichiro NakajimaDOI: 10.12659/MSM.947146
Med Sci Monit 2025; 31:e947146
Table 4 Baseline characteristics of the patients in each Porphyromonas gingivalis antibody titer group.
| Variables | Low group (n=8) | Medium group (n=14) | High group (n=8) | P value |
|---|---|---|---|---|
| Age (years) | 65 (46–71) | 70 (55–73) | 69 (68–74) | 0.447 |
| Sex (Female %) | 62.5% | 50.0% | 100.0% | 0.055 |
| Number of teeth | 27 (18–28) | 23 (18–27) | 21 (20–26) | 0.791 |
| Number of teeth with periodontal pocket depth 4–6 mm | 8 (3–11) | 5 (3–10) | 9 (8–11) | 0.278 |
| Number of teeth with periodontal pocket depth ≥6 mm | 0 (0–1) | 0 (0–1) | 1 (0–4) | 0.352 |
| Number of teeth with bleeding on probing | 1 (0–4) | 0 (0–2) | 3 (2–5) | 0.046* |
| PISA | 14.4 (0.0–220.6) | 0.0 (0.0–26.3) | 138.4 (70.5–284.2) | 0.124 |
| Periodontitis case definitions (no/mild/moderate/severe, n)# | 0/5/3/0 | 0/3/6/5 | 0/5/2/1 | 0.044* |
| Serum antibody titers (log.) | 0.00 (0.00–0.00) | 2.82 (2.60–3.09) | 3.60 (3.31–3.90) | 0.000** |
| (Baseline/0–12M, n) | ||||
| bDMARDs use | 0/1 | 0/4 | 0/1 | −/0.547 |
| csDMARDs use | 4/8 | 4/14 | 3/8 | 0.604/− |
| Steroid use (n) | 2/3 | 1/1 | 0/0 | 0.221/0.057 |
| Results are expressed as the median (interquartile range) or n (number). The values are the results of comparisons using Kruskal-Wallis test or chi-square test. * ** Significantly different between groups. bDMARDs – biological disease-modifying antirheumatic drugs; csDMARDs – conventional synthetic disease-modifying antirheumatic drugs. # The presence and severity of periodontitis were determined according to the Centers for Disease Control and Prevention in collaboration with the American Academy of Periodontology (CDC/AAP) case definition []. | ||||






